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Abstract 
  
Quorum sensing (QS) is a process of bacterial cell-to-cell communication that conveys 
population density information in order to coordinate gene expression to produce 
synchronized behaviors. QS regulates the expression of virulence genes in many species 
of bacteria; hence, the manipulation of QS pathways may lead to treatment options 
against many bacterial diseases. The LuxS enzyme converts S-ribosyl-L-homocysteine 
(SRH) into homocysteine (HCys) and 4(S),5-dihydroxypentane-2,3-dione (DPD), which 
is the precursor of autoinducer-2 (AI-2). Thus, inhibitors of LuxS could prevent QS by 
halting the conversion of SRH to AI-2 rendering the cell “uncommunicative”. This work 
shows the successful chemical synthesis of SRH and progress towards the synthesis of 
SRH analogs substituted at the HCys C3-position. The chemically-synthesized SRH can 
be utilized as the substrate for LuxS inhibition assays. The “HCys-C3” SRH analogs are 
designed to prevent the conversion of SRH to AI-2 by blocking the necessary association 
between the two LuxS monomers. This work also provided inspiration for the design and 
synthesis of other kinds of SRH analogs that could also serve as LuxS inhibitors.
 
 
1 
Chapter 1. Introduction 
 
Bacteria are typically considered to be unicellular, asocial, reclusive organisms. However, 
in recent years, it was found that bacteria operate in multicellular organization. They can 
talk with each other by using a chemical “language” and express collective behaviors. 
Bacterial cells make and secrete small signaling molecules like “words” into the 
environment and then recognize those “words” to perceive their population density. 
When bacterial cells accumulate to a certain density, they turn on group behaviors that are 
only successful when all of them participate in unison. This process of bacterial cell-to-
cell communication is termed quorum sensing (QS).
1
 It is regulated by small signaling 
molecules called autoinducers (AI’s). Bacterial cells produce and release AI’s into the 
environment. When the AI concentration has increased to a certain amount, they are 
locked down into receptors on the surface of bacteria, passing information into the 
bacterial cells. Thus, bacteria can acquire cell population density information and then 
monitor gene expression, resulting in changes to their collective behaviors including 
virulence, bioluminescence, biofilm formation, and motility (Figure 1.1).
2
   
 
 
 
 
Figure 1.1. Bacterial quorum sensing. Autoinducer molecules are synthesized by signal-
producing proteins (synthases) and detected by receptor proteins to influence collective behaviors 
through gene expression. 
 
 
2 
Two major QS systems exist in bacteria. System One QS mediates intra-species 
communication, while System Two QS mediates inter-species communication (Figure 
1.2). System One QS allows bacteria to perceive the population density of their own 
species. Through the System Two QS pathway, bacteria can take a census of the 
population of other species in the bacterial community. Thus, by possessing both systems, 
a bacterium is able to detect the population density of both its own species and other 
species in the environment, measure which is in the majority and which is in the minority , 
and decide what kind of social behavior to carry out.
1
 
 
Figure 1.2. System One and System Two QS in bacteria. Two blue ovals represent bacterial 
cells of the same species; they have intra-species communication. The green cell indicates another 
kind of bacterial species (different from blue ones), inter-species communication happens between 
it and the blue cells.    
 
1.1 System One Quorum Sensing: Intra-Species Communication 
 
In System One QS, bacterial communication is specific to its own species. Each signaling 
molecule can only fit with its own receptor and no other. Hence, different bacteria 
 
 
3 
communicate with their own species by using unique AI’s. By System One QS, bacteria 
can detect the cell number of their own species. Once the population density has reached 
a particular threshold, gene expression is initiated, allowing bacteria to coordinate 
collective behaviors. This circuit exists in both Gram-negative and Gram-positive 
bacteria.
1
 
 
1.1.1 System One Quorum Sensing in Gram-Negative Bacteria 
Acyl-homoserine lactones (AHLs) are the common autoinducers utilized by Gram-
negative bacteria (such as Vibrio fischeri) for intra-species QS. The concentration of 
AHLs increases as the bacterial cells’ population density rises. AHLs, which can freely 
come into and pass out of the cell, are produced by LuxI-type synthase proteins and 
detected by LuxR-type receptor proteins. The interaction between the LuxR proteins and 
the AHLs results in the specific binding of the LuxR-AHL complex to promoter DNA 
elements and the transcriptional activation of the target genes (Figure 1.3).
1
 
 
Figure 1.3. AHL-Based System One QS. (Filled green circles indicate AHLs.) 
Most AHLs reported to date share similar chemical structures: they all consist of an N-
acyl homoserine lactone and a R-group side chain (Figure 1.4 and Table 1.1).
3
 Different 
bacteria produce AHLs that differ in the length of the R-group tail. Chain lengths vary 
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from 4 to 18 carbon atoms and in some cases include substitution of a carbonyl at the 
third carbon.  
 
 
Figure 1.4. General AHL structure. Most AHLs share a N-acyl homoserine lactone head group. 
AHLs differ by the identity of the appended R-group tail. 
Each species of bacteria accomplishes intra-species communication using a specific 
autoinducer. However, some species of bacteria employ more than one AI (i.e. 
Pseudomonas aeruginosa, Table 1.1) in System One QS. In these cases, each AI has its 
own pair of synthase and corresponding receptor.
4
 
Table 1.1. Selected LuxI/R QS systems with corresponding AHL structures.
4
 
Bacterium AHL(s) LuxI/R homologs 
 
Agrobacterium 
tumefaciens 
 
 
TraI/R 
 
Chromobacterium 
violaceum 
 
 
CviI/R 
 
Vibrio fischeri 
 
 
LuxI/R 
 
 
 
 
Pseudomonas 
aeruginosa 
 
 
RhlI/R 
 
 
LasI/R 
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1.1.2 System One Quorum Sensing in Gram-Positive Bacteria 
To date, AHL-based QS has not been demonstrated in any Gram-positive bacteria. 
Instead, System One QS in Gram-positive bacteria is associated with the production of 
autoinducing peptides, or AIPs. Gram-positive bacteria (such as Streptococcus 
pneumoniae) synthesize peptides that are usually modified and then actively secreted. 
Detection occurs via a two-component signal transduction circuit, leading to the ATP-
driven phosphorylation of a response regulator protein, which then binds to promoter 
DNA and regulates transcription of target genes (Figure 1.5). As with the AHL-based QS 
system, some bacteria utilize more than one AIP as signaling molecules, each with its 
own pair of synthase and receptor (Table 1.2).
1
 
 
Figure 1.5. AIP-Based System One QS.
1
 (Wavy lines indicate AIPs.) 
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Table 1.2. Selected Gram-positive System One QS with corresponding AIPs.
1
(*geranyl group) 
Bacterial Species  AIP Name 
 
 
 
 
 
 
 
 
 
 
 
 
 
Staphylococcus 
aureus 
 
 
 
 
 
 
AIP-I 
 
 
 
 
 
 
AIP-II 
 
 
 
 
 
 
AIP-III 
 
 
 
 
 
 
AIP-IV 
 
Bacillus subtilis 
AlaAspProIleThrArgGlnTrp*GlyAsp ComX 
GluArgGlyMetThr CSF 
 
Streptococcus 
pneumoniae 
GluMetArgLeuSerLysPhePheArgAspPheIleLeuGln-  
CSP ArgLysLys 
 
1.2 System Two Quorum Sensing: Inter-Species Communication 
 
Bacteria can also communicate among different species, employing a universal signaling 
molecule termed autoinducer-2 (AI-2). In contrast to the AHLs and AIPs that are used as 
autoinducers for intra-species communication, AI-2 is a nonspecies-specific signaling 
molecule that mediates both intra- and inter-species communication among Gram-
negative and Gram-positive bacteria.
5
 
 
 
7 
AI-2-based inter-species QS was first established in the Gram-negative bacterium Vibrio 
harveyi, in which QS regulates the gene expression of a luciferase enzyme that results in 
bioluminescence.
6
 It was noticed by Bassler and coworkers that bioluminescence could be 
still observed when the System One AHL autoinducer HAI-1 (N-[3-(R)-
hydroxybutanoyl]-homoserine lactone, Figure 1.6, left) was absent.
7
 Thus, a second QS 
circuit was proposed in this bacterium to regulate the collective behavior of 
bioluminescence. Eventually, both the System Two QS circuit and its autoinducer AI-2 
(Figure 1.6, right) were elucidated; later it was shown that this System Two QS pathway 
is widespread in many bacterial species.
8
  
 
Figure 1.6. Autoinducer-1 and -2 in V. harveyi. 
System One and System Two QS circuits are parallel in V. harveyi. As shown in Figure 
1.7, LuxM is responsible for HAI-1 synthesis, while LuxS is responsible for AI-2 
synthesis. At high concentrations, HAI-1 and AI-2 are detected by LuxN and LuxP, 
respectively, leading to expression of the luxCDABE genes that initiate bioluminescence.
9
 
This well-studied System Two QS is considered to be a model for all System Two QS 
circuits that could be utilized for analysis of QS inhibition.
10
 
 
 
 
 
 
 
 
8 
 
Figure 1.7. Hybrid QS systems in V. harveyi.
1
HAI-1 is the autoinducer for System One QS, 
while AI-2 represents the autoinducer for System Two QS. Two QS Systems are parallel in V. 
harveyi. 
System Two QS has also been studied in the Gram-positive bacterium Bacillus subtilis. B. 
subtilis also has both System One and System Two QS circuits. It has peptide-based 
System One QS and also has luxS gene, conducting a typical LuxS catalyzed AI-2 
pathway at the same time.
1
 
 
1.2.1 AI-2 Biosynthesis  
The LuxS enzyme is responsible for AI-2 biosynthesis.
8
 It has a metabolic role in SAH 
detoxification in the activated methyl cycle in bacterial cells.
11
 The metabolite S-
adenosylmethionine (SAM), which exists ubiquitously in cells, is converted to S-
adenosylhomocysteine (SAH) via the action of methyltransferases (Mtf). SAH is 
hydrolyzed to adenine (Ad) and S-ribosyl-L-homocysteine (SRH) by the S-
adenosylhomocysteine nucleosidase (Pfs). Under the catalysis of S-
ribosylhomocysteinase (LuxS), SRH is then cleaved to 4(S),5-dihydroxy-2,3-
pentanedione (DPD) and homocysteine (HCys) (Figure 1.8).
12
  
 
 
9 
 
Figure 1.8. Biosynthesis of DPD. SRH generated from SAM converts to HCys and DPD under 
the catalysis of LuxS. 
DPD is the precursor of AI-2. It is unstable and rearranges spontaneously to generate a 
variety of interconverting derivatives, each with the potential capability of mediating 
bacterial interspecies communication. In aqueous solution, there is spontaneous 
cyclization of DPD to either the S or R form of 2,4-dihydroxy-2-methyldihydro-3-
furanone (DHMF), which after hydration form S or R of 2-methyl-2,3,3,4-
tetrahydroxytetrahydrofuran (THMF), respectively. The R-THMF isomer serves as AI-2 
in Salmonella typhimurium. If there is enough borate in solution, the S-THMF undergoes 
boronation to generate the furanosyl borate diester S-THMF-borate that is AI-2 in Vibrio 
harveyi.
5b, c
 The interconversion of different DPD derivatives that exist in equilibrium 
(known as the AI-2 pool) allows bacteria to recognize the AI-2 of their own species and 
the AI-2 secreted by other bacterial species. Thus, AI-2 can serve as the universal 
“language” for bacterial interspecies communication.5b, 13 
 
 
 
 
 
 
 
 
10 
 
 
 
 
 
Figure 1.9. AI-2  pool.
5c
 DPD is quite unstable and can be transformed into many forms in 
aqueous solution. S-THMF-borate is the product from boration of S-THMF and is the AI-2 in 
Vibrio harveyi, while  the R-THMF isomer represents the AI-2 in  Salmonella typhimurium. 
Different bacterial species own its unique AI-2 to conduct inter-species communication.   
 
1.2.2 Catalytic Mechanism of LuxS  
Pei and coworkers first reported the mechanism for the LuxS-catalyzed cleavage of SRH 
into HCys and DPD.
12, 14
 The LuxS enzyme contains an iron (II) cation in the active site, 
which stabilizes various intermediates in the pathway for the LuxS-catalytic cleavage by 
binding to them. In the initial steps of the reaction (Figure 1.10, steps a-e), LuxS binds to 
the ring-opened hydroxyaldehyde form of SRH; the metal ion acts as a Lewis acid and 
amino acid residues Cys84 and Glu57 act as Lewis bases, promoting iterative 
isomerization and migration of the α-hydroxycarbonyl unit proceeding through 
intermediates 1-3 and 1-5. Finally, elimination of homocysteine produces the enol 
intermediate 1-7, which immediately rearranges to DPD (Figure 1.10, step f-h). 
 
 
11 
 
Figure 1.10. Catalytic mechanism of LuxS elucidated by Pei.
12
 
 
1.3 Modulation of AI-2-Based Quorum Sensing  
 
As noted earlier, bacterial QS regulates group behaviors including virulence, motility, and 
biofilm formation in bacteria. These behaviors are correlated with pathogenicity,
15
 and 
mutants that are deficient in QS often fail to establish infections.
5a, 10b, 15b, 16
 Thus, the 
study of QS could lead to a new pathway towards the treatment of bacterial diseases: if 
communication between bacteria could be prevent, then patients will not be infecte. 
  
Since the AI-2 system is species-nonspecific and exists in both Gram-negative and Gram-
positive bacteria, System Two QS is a promising target for the development of broad-
spectrum antibiotics.
15a
 The luxS gene, which encodes for the LuxS synthase, has been 
found in over 70 bacterial species (Table 1.3).
17
 The development of small molecules as 
potential drugs to control these pathogens through System Two QS could be a novel way 
 
 
12 
to treat bacterial infectious diseases. The particular advantage of these sorts of drugs is 
that they will not kill the bacteria like traditional antibiotics do. Thus the bacteria should 
not experience much selective pressure to develop resistance, which is a big problem with 
today’s medicines. 
Table 1.3. System Two QS regulated pathogenic bacteria.
17
 
Bacteria species Diseases AI-2 QS Regulated 
Phenotype 
Borrelia burgdorferi Lyme disease Pleiotropic protein 
expression 
Campylobacter jejuni Food poisoning Motility 
Clostridium perfringens Food poisoning Toxin production 
Escherichia coli Intestinal and extra-intestinal 
infections  
Virulence 
Neisseria meningitidis Bacterial meningitis 
(epidemic) 
Bacteremic infection 
Salmonella typhimurium Gastroenteritis  Biofilm formation 
Vibrio cholerae Cholera Virulence 
 
One way to block the System Two QS is to interact with AI-2 receptors. In this case, it is 
proposed that bacteria would not be able to communicate even when the AI-2 has 
accumulated to the threshold concentration in the presence of receptor inhibitors. For 
example, Kim Janda’s research group has reported a series of design and synthesis of AI-
2/ DPD analogs while some of them were found to be effective against either V. harveyi 
or S. typhimurium.
18
 However, each bacterial species has its own AI-2, which complicates 
the design of small molecules for the modulation of different AI-2 receptors, and the 
rational design of new ligands for AI-2 receptors interaction has not really been pursued 
to date.
19
 A better way to prevent the System Two QS pathway is by LuxS activity 
inhibition. SRH is converted to HCys and DPD by LuxS and DPD is the precursor 
molecule of AI-2. Thus, the LuxS enzyme is responsible for AI-2 biosynthesis.
13
 Small 
 
 
13 
molecules that inactivate LuxS would prevent AI-2 formation and therefore the bacteria 
could not communicate population density information. Since LuxS is not found in 
humans, the inhibition of LuxS will not have effect on human bodies. 
 
1.3.1 LuxS Inhibitors in the Chemical Literature  
Several research groups have reported progress towards the synthesis of small molecules 
as potential LuxS inhibitors to date (Table 1.4).
19
 All of them focus upon the 
modification, particularly at the ribose moiety, of the SRH molecule itself or its 
intermediates involved in the LuxS-catalyzed cleavage to DPD. 
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Table 1.4. Summary of published SRH analogs as potential LuxS inhibitors. Compound 1-14 
and 1-15 (in red) were evaluated as the best inhibitors so far. 
 
 
1-8
20
 
 
 
1-9
20
 
 
 
1-10
20 
 
 
                1-11
21
 X = H; 
                1-12
21
 X = CF3. 
 
 
 
 
1-13
21 
 
 
 
1-14
15b 
 
1-15
15b 
 
 
1-16
15b 
 
 
1-17
15b 
 
 
 
1-18
15b 
 
 
 
 
1-19
15b 
 
1-20
15b 
 
 
 
 
         1-21
22
 X = OH, Y = H; 
         1-22
22
 X = H, Y = OH; 
         1-23
22
 X = H, Y = H. 
 
         1-24
22
 X = OH, Y = H; 
         1-25
22
X = H, Y = OH. 
 
 
 
   1-26
23
 X = H, Y = H; 
   1-27
23
 X = OMe, Y = H; 
   1-28
23
 X = H, Y = OMe. 
 
                
               1-29
23
 R = H; 
               1-30
23
 R = Me. 
 
 
 
 
1-31
23 
 
 
 
 
            1-32
23
 X = Br; 
            1-33
23
 X = F. 
 
S
NH2
HO2C
O
OHH
F OR
S
NH2
HO2C
O
X OH
OH
 
 
15 
According with Zhou’s publication in 2004, the hemiacetal of SRH was replaced by an 
ether group to form compound 1-8, which could potentially bind to LuxS in a similar 
manner as SRH but would not be hydrolyzed to form DPD because of the lack of initial 
aldose-ketose isomerization in SRH hydrolysis. The position of the S-C bond of SRH was 
changed in compound 19, which was expected to block the cleavage of S-C bond. 
However, compound 1-9 could still bind to LuxS in a similar orientation as SRH since 
their amino acid moieties and ribose moieties are connected by the same number of C-C 
and C-S bonds. Results showed that the LuxS enzyme did not break the S-C bonds in 
compounds 1-8 and 1-9 and therefore both of them could be potential LuxS inhibitors.
20
 
Considering this result with Zhao’s previous report that SRH analogs 1-10 to 1-13 were 
not effective in LuxS inhibition
21
, it may be concluded that the amino acid part in SRH 
plays a key role in substrate binding to LuxS. 
 
Compounds 1-14 to 1-20 reported by Shen et al. had structures similar to those of 
intermediates 1-4 and 1-5 in the mechanism of LuxS-catalyzed cleavage of SRH (Figure 
1.10). Kinetic studies showed that compounds 1-14 and 1-15 had good KI values of 0.72 
and 0.37 μM, respectively, in the evaluation of native Co(II)-substituted B. subtilis LuxS 
(Co-BsLuxS) enzyme inhibition. To explain the results, the authors stated that 1-14 and 
1-15 are more stable isomers with tight binding to LuxS than 1-4 and 1-5 and therefore 
could slow or prevent the catalytic transformation. However, it was found that 
compounds 1-14 and 1-15 were less effective against Zn(II)-substituted B. subtilis LuxS 
(Zn-BsLuxS) and Co(II)-substituted E. coli (Co-EcLuxS) and V. harveyi (Co-VhLuxS) 
LuxS.
15b
 
 
Wnuk et al. reported the synthesis of SRH analogs 1-21 to 1-25 with the ribose-C5 
position replaced by fluoro vinyl groups. The authors hypothesized that LuxS may be 
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able to add water to the double bonds of these analogs, resulting in inactivation of the 
LuxS enzyme. One of the compounds 1-23 acted as a competitive inhibitor with moderate 
potency against BsLuxS.
22
 In Wnuk’s later report, SRH analogs (1-26 to 1-33) modified 
at the ribose-C3 position were synthesized and evaluated in the inhibition of BsLuxS and 
VhLuxS. The most potent compound was 1-31 with inverted stereochemistry at the 
ribose-C3 position. Compounds 1-32 and 1-33 were identified as time-dependent 
inhibitors of LuxS.
23
 
 
Based on overall biological evaluation, the best potential LuxS inhibitors reported so far 
are compounds 1-14 and 1-15. However, there is still much room for improvement on the 
design and synthesis of better LuxS inhibitors since all of the published SRH analogs are 
not functioned as LuxS inhibitors in vivo. 
 
1.4 Dimerization Inhibitors 
 
Since many enzymes are homodimers or multimers, disruption of the interactions 
between protein subunits provides another reasonable way for enzyme inhibition. Two 
primary examples are dimerization inhibitors of HIV-1 reverse transcriptase (HIV-1 RT) 
and of inducible nitric oxide synthase (iNOS) from the literature.
24
 The first example of a 
small non-peptidic molecule able to interfere with the dimerization process of HIV-1 RT 
is TSAO-T (tert-butyldimethylsilyl-spiro-amino-oxathiole-dioxide, Figure 1.11).
24a
 HIV-
1 RT is an asymmetric heterodimer that is composed by two subunits named p66 and p51.  
The most important region of the p66-p51 dimer interface is the β7-β8 loop in p51, which 
builds a pathway towards the non-nucleoside reverse transcriptase inhibitor (NNRTI) 
binding pocket and constitutes the binding site for dimerization in the p66 subunit. This 
loop of the p51 subunit is required for both the catalytic function of the p66 subunit and 
 
 
17 
the RT dimerization. Based on this information of p66-p51 dimer interface and the 
structure of the substrate, TSAO-T was developed by Camarasa’s group that has unique 
selectivity for HIV-1 through a specific interaction with the p51 subunit of HIV-1 RT, 
preventing the dimerization of p51 with p66.
24a
 
 
Figure 1.11. Chemical structure of TSAO-T. It is the first reported dimerization inhibitor fo r 
HIV-1 RT. 
 
1.4.1 Proposed LuxS Dimerization Inhibitors  
As a relatively small dimer (35 kDa) with 23% of its surface area buried at the dimer 
interface, the LuxS enzyme is a good candidate for dimerization inhibition. The SRH 
binding site is buried in the LuxS dimer and the two monomers of LuxS do not contribute 
to the binding equally.
25
 Instead, one monomer (monomer A, Figure 1.12. yellow) which 
contains the metal ion (Fe
2+
) contributes more substrate-binding residues, while the 
second monomer (monomer B, Figure 1.12. green) that carries the catalytic residue 
Cys84 contributes fewer. If a small molecule could maintain tight binding with monomer 
A of LuxS while preventing proper association with monomer B, which plays the key 
catalytic role in the cleavage of SRH to DPD, AI-2 biosynthesis could be controlled.  
 
 
18 
              
(a) 
 
(b) 
Figure 1.12. (a) X-Ray crystal structure of LuxS protein.
25
 (b) LuxS Binding Site.25 (Yellow – 
Monomer A; green – Monomer B, magenta – ligand; red – residues contributed by Monomer A; 
blue – residues, including the catalytic parts Cys84, contributed by Monomer B; sticks – binding 
site residues; *HCys-C3 position.) 
 
Based on our detailed knowledge of the SRH binding site from the solved LuxS X-ray 
crystal structure, we have proposed SRH analogs with the potential to serve as LuxS 
inhibitors (Figure 1.13). By the introduction of sterically-demanding groups (alkyl or 
aryl) at the HCys-C3 position of SRH (Figure 1.12b & 1.13. position labeled *) these 
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analogs could potentially bind with monomer A (Figure 1.12b.  yellow) while blocking 
the correct association of monomer B (Figure 1.12b. green). Thus, the activity of LuxS 
would be inhibited and quorum sensing would be prevented by blocking AI-2 production, 
rendering all cells “mute” in a bacterial population. In contrast to previously-reported 
LuxS inhibitors that typically focus on the modification of the ribose part of SRH (see 
Section 1.3.1)
20, 23
, these molecules focus on the modification of the homocysteine part to 
modulate the activity of LuxS enzyme by acting as potential dimerization inhibitors. At 
this time, no one has reported the synthesis of such kind of SRH analogs. The chemical 
synthesis of these HCys-C3 analogs, and of the SRH substrate itself, is detailed in the 
chapters that follow. 
 
Figure 1.13. Proposed LuxS inhibitors. 
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Chapter 2. Chemical Synthesis of S-Ribosyl-L-homocysteine (SRH) 
 
The first task was to chemically synthesize SRH. The motivation was twofold: (i) to 
acquire sufficient quantities of SRH to serve as the substrate for LuxS activity/inhibition 
assays and (ii) to develop the skills necessary to synthesize analogs of SRH later on. The 
general idea behind the synthesis of SRH is to obtain both an amino acid moiety (Figure 
2.1. red) and a ribose moiety (Figure 2.1. blue), and then build a S-C bond (Figure 2.1. 
black bold) between them through a coupling reaction. 
 
Figure 2.1. Cyclic and ring-opened forms of SRH. The cyclic form of SRH can have either of 
two stereochemical arrangements:  or . Left to right: -cyclic form, ring-opened form, -cyclic 
form. (Red – amino acid moiety, black bold – S-C bond, blue – ribose moiety.) 
 
2.1 First Attempt – Unsuccessful Implementation of Literature Precedent 
 
The first chemical synthesis of SRH was reported from Guillerm et al. in 1991 with a low 
yield of ~5% over eight linear steps.
26
  This chemically synthesized SRH was specifically 
tritiated at the ribose-C5 position and used to assay SRH hydrolase. Their key step was 
the nucleophilic substitution of C5-ribosyltosylate with the disodium salt of L –
homocysteine to form a S–C bond. Later on Zhao laboratory published another more 
straightforward synthetic method with only five linear steps with a higher overall yield of 
~52%.
21
 In this straightforward method (Scheme 2.1), the amino and carboxyl groups in 
(L, L)-homocystine were protected in two steps as tert-butyl carbamate (Boc) and methyl 
ester, respectively. The key step was the S–C bond formation, effected by a modified 
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Mitsunobu coupling between the fully protected homocystine and the D-ribose 
derivative.
27
 Fully-protected S-ribosylhomocysteine was then deprotected by standard 
procedures resulting in the trifluoroacetic acid (TFA) salt of SRH. 
 
 
 
 
Scheme 2.1. SRH synthesis reported by Zhao et al.
21
 Mitsunobu-type coupling of protected 
homocystine to ribose moiety effected the S-C bond (the third step above). 
 
Our attempt to implement this synthetic procedure (shown in Scheme 2.2) began with 
commercial D-ribose and (L,L)-homocystine. Ribose derivative 1 and the fully protected 
homocystine 2a were successfully obtained in 66% and 88% yields, respectively. 
However, in our hands, the Mitsunobu-type coupling of compound 1 with compound 2a 
failed after repeated attempts, either under the presence of tri-ethylphosphine (Et3P) as in 
Zhao’s protocol or tri-n-butylphosphine (n-Bu3P) that also serves as a catalyst for this 
type of reaction.
27
 Even after modification of the experimental procedure (i.e. adjusting 
the reagent equivalents, prolonging or reducing reaction time, and lowering the reaction 
temperature), S-C bond formation was still unsuccessful.  
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Scheme 2.2. Unsuccessful attempt of HCys-ribose coupling. Reaction conditions: a. 
MeOH/acetone, conc. HCl, reflux, 1.5 h; b. (i) MeOH, SOCl2, 0 
o
C-rt, Ar, 3 d; (ii) (Boc)2O, 
dioxane/Na2CO3(aq), 0 
o
C-rt, overnight; c. Et3P (or n-Bu3P), pyridine, rt, Ar, 3 d. 
 
We utilized both thin layer chromatography (TLC) and nuclear magnetic resonance 
(NMR) methods to analyze the crude product of the attempted coupling reaction. Our 
TLC plate for the crude product of coupling reaction showed several new spots with 
different Rf values from compound 1 and 2a, which suggested a decomposition happened 
(see Appendix 7.1). Additionally, neither any proton peaks that would indicate the 
existence of starting materials (compound 1 and 2a) nor new proton peaks that would 
suggest the S-C bond formation were observed in the 
1
H NMR spectrum of the crude 
product, indicating that the coupling reaction failed. Thus, decomposition was observed 
after purification rather than desired fully protected ribosylhomocysteine product. 
 
The Mitsunobu-type reaction used to create the S-C bond in Zhao’s synthesis can be 
broken down into two steps: (1) the cleavage of the S-S bond in protected disulfide 2a 
and then (2) SN2-type coupling with ribose moiety 1. At first, it was hypothesized that the 
failure of the Mitsunobu reaction might be attributable to the lack of initial cleavage of 
the S-S bond. To test this hypothesis, we ran a single-step reaction to determine if 
disulfide 2a could convert to thiol (-SH) under the Mitsunobu conditions. The protected 
disulfide 2a transformed to thiol 3a under the presence of tri-n-butylphosphine 
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successfully in nearly quantitative yield after flash column chromatography purification 
(followed by 
1
H NMR characterization).
 a
 Thus our initial hypothesis was disproved by 
this result. 
 
 
 
Scheme 2.3. Initial step of modified Mitsunobu reaction – cleavage of the S-S bond. 
 
Therefore, it was concluded that the reason for the failure of the Mitsunobu reaction must 
be unsuccessful nucleophilic substitution between the 5-hydroxyl group of the ribose and 
the thiol/thiolate of fully protected homocysteine. To overcome this problem, one or both 
better coupling partners (either in place of the ribose moiety 1 and/or amino acid moiety 
2a) would be required to be utilized in the nucleophilic substitution. 
 
2.2 Second Attempt – Successful Synthesis of SRH (without Quantification) 
 
A second attempt at the synthesis of SRH was inspired by the work of Wnuk et al 
(2009)
23
, who reported the synthesis of several modified SRH analogs as potential LuxS 
inhibitors, including 3-deoxy-SRH (Scheme 2.4). Mesylation at the 5-free hydroxyl group 
of the ribose, displacement with the thiolate derived from D/L-homocysteine under basic 
(NaOH) conditions, and treatment with aqueous trifluoroacetic acid (TFA) gave the 
desired 3-deoxy-SRH analog that lacks a hydroxyl group at the ribose C-3 position. 
 
 
                                                 
a . The nearly quantitative yield was determined by weight after column chromatography 
purification and then 
1
H NMR was utilized to characterize the purity of thiol 3a.  
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Scheme 2.4. Wnuk’s synthesis of SRH analog modified at the ribosyl C-3 position.23 Reagents: 
(a) MsCl/Et3N, 97%; (b) D/L-HCys/NaOH/MeOH/H2O, 31%; (c) TFA/H2O, 90%. 
 
In accordance with this publication, we applied synthesized ribosyl mesylate 4a to couple 
with commercial D/L-homocysteine (D/L-HCys) that effected the S-C bond formation 
successfully. After a standard deprotection procedure by TFA, the desired product 
SRHTFA salt was obtained (Scheme 2.5).  
 
 
 
 
 
 
 
 
 
Scheme 2.5. Successful coupling of HCys and activated ribose moiety. Reaction conditions: a. 
MsCl, Et3N, DCM, 0 
o
C–rt, Ar, 30 min, 99%; b. 1 M NaOH/H2O, 60 
o
C, Ar, overnight; c. 
TFA/H2O, 0 
o
C–rt, 3 h. 
O
HO
O
O
O
MsO
O
O
O
O
O
HO
S
NH2
O
OHO
S
NH2
O
OH
OH
a
c
b
 
 
25 
In comparison to Zhao’s method (shown in Scheme 2.1), this synthetic route has several 
advantages. Firstly, the free 5-hydroxyl group of the ribose is as converted into the 
mesylate, which was a better leaving group than the hydroxyl group in substitution 
reactions. Secondly, the native D/L-HCys, with its free thiol group, was utilized here 
instead of protected homocystine, avoiding the S-S bond cleavage step. Apparently, in 
our hands the pair of ribosyl mesylate 4a and unprotected HCys were better coupling 
partners than ribose moiety 1 and fully protected homocystine 2a utilized by Zhao. 
Finally, this synthetic method needed fewer steps to obtain the final product SRH, which 
could possibly improve the overall yield of the reaction sequence.  
 
However, this synthetic method posed insurmountable disadvantages as well. Firstly, the 
coupling reaction utilized aqueous solution as solvent. Since the protected SRH 5 is a 
water-soluble compound, this meant the product could contain some residual water from 
the solvent,
 b
 which is undetectable by routine analysis (i.e. 
1
H NMR). Secondly, the 
coupling of key compounds 4a and HCys using NaOH produced an inseparable salt 
byproduct (NaCl) in addition to the protected SRH 5. Even though the mixture produced 
the desired (+/-)-SRHTFA salt (as characterized by 1H NMR, see Appendix 7.2) in the 
next deprotection step, the byproduct salt still persisted in the final product since our yield 
of (+/-)-SRHTFA was far over 100%. It was difficult to isolate this byproduct from the 
final product (+/-)-SRHTFA salt because both salts are water-soluble.c In Wnuk’s report, 
a high performance liquid chromatography (HPLC) method was applied to purify the 
SRH. However, due to a limitation of facilities in our department, the HPLC purification 
method was impractical; in order to obtain sufficient quantities of SRH, several days of 
continuous work and a prep-scale column would be required.  
                                                 
b. Separation funnel technique (solvent system CH2Cl2/H2O) failed to extract compound 5.  
c. Recrystallization from MeOH attempted but failed. 
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Instead, we introduced C18 SEP-PAK cartridges (Water Associates, Inc.) here to purify 
the SRH. The sorbent of C18 cartridge is made of a silica-based bonded phase with strong 
hydrophobicity. It can adsorb analytes of weak hydrophobicity from aqueous solutions 
and becomes a convenient method in the solid phase extraction. It has similar behavior 
with reversed-phase HPLC columns, but much smaller and without the need for 
specialized equipment.
46
 To purify SRH with C18 cartridges, first an aqueous solution of 
the mixture containing SRH and byproduct salt was made. It was expected that the SRH 
would be absorbed by the cartridges while the byproduct salt would elute with the 
residual aqueous solution. Then the SRH could be washed from the cartridges in a 
separate step using a less polar solvent (i.e. MeOH or acetonitrile) and concentrated by 
rotary evaporation. After purification by C18 cartridges (initial weight of crude product ~ 
0.8 g) in this manner, we obtained a product with fewer impurities, as indicated by its 
reduced weight (~ 0.3 g, see Appendix 7.3). However, it was inferred that the byproduct 
salt still persisted in the product since the yield of SRH was still over 100% of theoretical. 
As this byproduct salt was undetectable by NMR, we could not determine the exact yield 
of the SRH through this method. 
 
The fact that these (+/-)-SRHTFA crystals might contain some amount of residual water 
and byproduct salt meant that we could not accurately determine the exact amount of  
(+/-)-SRH produced by our synthetic protocol by weight. This was problematic, as SRH 
is meant for use in a biochemical assay to determine the catalytic activity of LuxS in the 
presence and absence of putative inhibitors and therefore needs to be quantified exactly. 
To address this issue, a fluorescamine quantification method for (+/-)-SRH in aqueous 
solution was attempted in the lab by Richa Gupta.
45
 However, this biochemical assay 
proved unreliable, with non-reproducible results and unacceptably high error when used 
to quantify known standards. Therefore, an alternate synthetic method, one that would 
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produce SRH cleanly without inseparable, undetectable byproducts was necessary. 
 
2.3 Third Attempt – Successful Synthesis and Quantification of SRH 
 
An alternate synthetic approach to the formation of the S-C bond of SRH was also 
reported by Wnuk for the synthesis of a different SRH analog, S-(5-deoxy-D-
xylofuranos-5-yl)-L-homocysteine (SXH) (Scheme 2.6).
23
 Here, a protected homocysteine 
(BocNH–CH(CH2CH2SH)–CO2t-Bu) and an activated ribose moiety were used in the 
coupling reaction under the presence of n-BuLi as the base for SN2 substitution. 
 
 
 
 
 
 
 
 
Scheme 2.6. Wnuk’s synthesis of SXH.23 Reagents and conditions: (a) SOCl2/Et3N/DCM/-78 
o
C 
to rt, yield 74%; (b) RuCl3/NaIO4/CCl4/CH3CN/H2O/0 
o
C to rt, yield 67%; (c) (i) BocNH–
CH(CH2CH2SH)–CO2t-Bu/BuLi/DMF/0 
o
C to rt, (ii) THF/H2SO4/H2O/0 
o
C; (d) TFA/H2O/0 
o
C to 
rt, yield 61%. 
 
Inspired by Wnuk’s synthesis of SXH, a sequence was initiated to synthesize SRH 
utilizing protected homocysteine derivatives 3 and activated ribose moieties 4 in a 
coupling reaction with n-BuLi (Scheme 2.7). For the amino acid moiety (refer to Figure 
2.1), a fully protected homocysteine 2 was utilized as in Zhao’s synthesis but converted to 
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the free thiol 3 as in Wnuk’s application of free HCys to the synthesis of 3-deoxy-SRH. 
For the ribose moiety 4 (refer to Figure 2.1), a good leaving group was introduced as in 
Wnuk’s synthesis of SXH. According with Wnuk’s report, the use of anisole in addition 
to the mixture of trifluoroacetic acid (TFA) and water at the final deprotection step also 
proved a beneficial modification.
23
 Gratifyingly, compound 7 was satisfactorily purified 
and quantified before the near-quantitative conversion to the TFA salt of SRH 8, which 
could be lyophilized to a pure, powdery solid that could be easily measured by weight. 
Another benefit of this synthetic method is its use of enantiomerically pure materials to 
produce the single desired isomer of SRH in very good overall yield (~60% over five 
linear steps).  
 
 
 
 
 
 
 
Scheme 2.7. Successful hybrid method of SRH synthesis . Reaction conditions: (a) (i) 10% 
Na2CO3 (aq)/dioxane, (Boc)2O, 0 
o
C-rt, overnight, (ii) tert‐ butyl‐ 2,2,2‐ trichloroacetimidate, 
DCM, Ar, rt, overnight, 90%; (b) n-Bu3P, DMF/ H2O, Ar, rt, overnight, without purificat ion used 
for next step; (c) n-BuLi, DMF, Ar, 0 
o
C–rt, overnight, 70%; (d) TFA/anisole/H2O, 0 
o
C–rt, 6 h, 
94%. 
 
In a separate effort towards the synthesis of SRH HCys-C3 analogs (see Section 3.1), we 
had observed that free thiol 14b was prone to be oxidized into disulfide 14a when 
exposed to air (see Appendix 7.4). Thus, in later implementations of the hybrid method of 
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SRH synthesis shown in Scheme 2.7, purification of thiol 3b was skipped in order to 
prevent contact with air (see experimental procedure of compound 7 in Chapter 5.). The 
coupling reaction was still successful, and with a good yield of 70%, which means the 
existence of tri-n-butylphosphine does not effect the success of coupling reaction. Thus, 
the cleavage of disulfide and the coupling reaction could be combined as one step, which 
is corresponding with the Mitsunobu-type coupling implemented by Zhao originally 
(Scheme 2.1). 
 
2.3.1 Impact and Future Applications of Revised Synthesis   
To evaluate our synthesized SRH obtained by the third synthetic method, it was utilized 
as the substrate in an Ellman’s assay for LuxS activity (Figure 2.4).45 This chemically 
synthesized SRH was effective to be used as the substrate in the determination of LuxS 
activity (see Appendix 7.5).
d 
 
 
In addition, a general idea was concluded towards the synthesis of SRH or its analogs: (i) 
obtaining a homocysteine moiety and a ribose moiety; (ii) then building a S-C bond 
between the two moieties. Particularly, considering that the S-C bond formation is the key 
step for the synthesis of SRH, it is interesting to note that the identity of both the 
protecting group R’ on the carboxylate 3 and the leaving group R on the ribose moiety 4 
had a significant effect on the success of this coupling reaction. In no combination did the 
use of methyl protection on 3 or mesylate activation on 4 result in successful formation of 
the S-C bond (Scheme 2.9).  
 
                                                 
d. Biological assays were performed by Richa Gupta. 
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 Mesylate (Ms) 4a Tosylate (Ts) 4b 
Methyl (Me) 3a     
Tert-butyl (tBu) 3b    
Scheme 2.9.  Coupling results of combinations of protecting groups and leaving groups. 
 
This information, obtained after extensive troubleshooting (note that the original 
synthesis of Zhao utilized 2a rather than 2b, and that of Wnuk, which was successful in 
our hands, utilized 4a rather than 4b), could be used to inform the synthetic pathways 
towards SRH analogs (Chapter 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
Chapter 3. Synthesis of SRH Analogs  Modified at the Homocysteine-C3 Position 
 
As LuxS is responsible for the biosynthesis of AI-2, small molecules that inhibit LuxS 
dimerization could prevent quorum sensing by blocking AI-2 production. Since it is 
known that SRH binds in the middle of LuxS dimer, this protein is a good candidate for 
dimerization inhibition. The introduction of a bulky steric group at the HCys-C3 position 
of SRH could potentially prevent the correct association of the two monomers of LuxS. 
Therefore, these SRH analogs modified at the HCys-C3 position are potential inhibitors 
of LuxS. 
 
 
Figure 3.1. Cyclic and ring-opened forms of SRH HCys-C3 analogs. The cyclic form of SRH 
analogs modified at the HCys-C3 position can have either of two stereochemical arrangements:  
or . Left to right: -cyclic form, ring-opened form, -cyclic form. (Red –  modified homocysteine 
moiety, black bold – S-C bond, blue – ribose moiety, *HCys-C3 position.) 
 
Similar to the synthesis of SRH, the synthesis of these HCys-C3 derivatives can be 
broken down into two phases: the synthesis of a modified homocysteine moiety 
containing an additional “R” group at the HCys-C3 position* (Figure 3.1. red) and the 
coupling of this novel amino acid moiety with the ribose moiety as in SRH synthesis 
(Figure 3.1. blue).  
 
3.1 First Attempt – Mannich Reaction Approach 
 
It was initially proposed that SRH analogs with substitution at the HCys-C3 position 
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could be synthesized from commercial compounds ethyl glyoxylate, p-anisidine, and 
ribose according to the retrosynthesis shown in Scheme 3.1.  
 
 
 
 
 
 
 
 
Scheme 3.1. Retrosynthetic analysis of SRH HCys-C3 analogs.
 
(P1, P2 = protecting groups)
 
 
Imine c, which could be obtained from the reaction between commercial ethyl glyoxylate 
b and p-anisidine a, could be coupled with aldehyde d in the next step of Mannich 
reaction. Then the obtained Mannich-type aldehyde product e  could be reduced to alcohol 
f through a standard reduction procedure. The free hydroxyl group of the alcohol could be 
protected into either mesylate or tosylate g, both of which could be transformed into 
thioesters h later. Then the thioester h could be deprotected into thiol i, which is the 
desired HCys moiety with a substitution at the C3 position. Then the HCys-C3 moiety i 
could be coupled with ribose j to obtain the protected SRH k. After a standard 
deprotection procedure, the SRH HCys-C3 analog l could be obtained. 
 
The Mannich reaction is the key step in this reaction sequence, completing the 
substitution of the HCys-C3 position with the new “R” group (Scheme 3.2). Barbas et al 
reported an asymmetric Mannich reaction coupling the imine derived from ethyl 
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glyoxylate and p-anisidine
28
 with unmodified aldehydes, such as propionaldehyde (R = 
CH3), butyraldehyde (R = CH2CH3), etc., catalyzed by L-proline in DMSO at room 
temperature. This L-proline catalyzed Mannich reaction mechanism is stereoselective 
with a preference for the product having (S, S) configuration (Figure 3.2).
29
 It is proposed 
that the imine can react with different aldehyde donors to produce a series of Mannich 
products with different “R” groups. 
 
 
 
Scheme 3.2. Mannich reaction. (Proposed substituents: R = Me, Et, i-Pr, t-Bu, Ph.) 
 
 
Figure 3.2. Mechanism of L-proline catalyzed asymmetric Mannich reaction. It is prone to 
form (S, S) confirguration product.
30
  
 
Our initial approach to the synthesis of SRH HCys-C3 analogs began with the synthesis 
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of the modified homocysteine moiety (Figure 3.1. red) to be later coupled with an 
appropriate ribose moiety (Figure 3.1. blue), according to the protocol established in 
Chapter 2.  
 
The synthetic pathway towards the synthesis of modified homocysteine moiety with a 
methyl substituent (R = Me) at the C3 position is shown in Scheme 3.3. Imine 9 was 
derived straightforwardly from commercial ethyl glyoxylate and p-anisidine and was of 
sufficient purity to be used for next step without purification.
28 The asymmetric Mannich 
reaction between imine 9 and propionaldehyde was carried out using L-proline as the 
catalyst, which gave the key methyl-substituted β-amino aldehyde 10 {with presumed 
stereochemistry of (S, S)} in 49% yield after silica gel column chromatography 
purification.
29
 After standard reduction by sodium borohydride, alcohol 11a was obtained 
and then converted to mesylate 12 in 87% yield over two steps. The conversion of 11a to 
tosylate (OHOTs) was unsuccessful; decomposition was observed after repeated 
attempts. According with the standard procedures from published references, mesylate 12 
was converted in two steps into a mixture of disulfide 14a and thiol 14b.
31, 32
 Since only 
thiol 14b was required for the subsequent coupling reaction, disulfide 14a was 
transformed into thiol by a standard cleavage under the presence of tri-n-
butylphosphine.
33
 After this standard conversion, the overall yield of 14b from 13 was 
improved substantially (from 15% to 65% over 2 steps).  
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Scheme 3.3. Successful synthesis of HCys-C3 substituted moiety. 
 
Next we attempted to utilize ribose moieties 1, 4a and 4b, as used in the synthesis of SRH 
to couple with C3-methyl homocysteine moiety 14b, in which compound 4b had 
successfully worked in the SRH synthesis in our hands. However, the coupling reaction 
was unsuccessful, resulting in decomposition of compound 14b and all ribose moieties. 
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Scheme 3.4. Unsuccessful coupling between the C3 substituted homocysteine moiety with 
three ribose moieties utilized in the synthesis of SRH or analogs. Additional deprotection steps 
would be required to produce the final SRH C3 analog. 
 
Our prior studies into the synthesis of SRH (see Chapter 2) demonstrated that the identity 
of protecting groups on the HCys moiety could have a significant effect upon the success 
of the coupling reaction. The possible reason for the failure of this initial approach to 
synthesis of SRH HCys-C3 analogs could be the different protecting groups of the 
modified homocysteine moiety 14b (Et and PMP) as compared to those of compound 3b 
(t-Bu and Boc) as shown in Figure 3.2.   
 
3.2 Second Attempt – Protecting Group Modifications of C3-Substituted HCys 
 
Based on our acknowledgement that the protecting groups of the amino acid moiety likely 
have a great effect on the coupling reaction, our next efforts were focused on the 
synthesis of the target compound 15 shown in Figure 3.3. It has a similar structure to 
compound 3b, which was previously successfully coupled with ribose derivative 4b 
except for the substitution at the C3 position. 
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Figure 3.3. Target C3 position substituted homocysteine moiety 15. Desired compound 15 has 
the same protecting groups as compound 3, which is the homocysteine moiety used in the 
successful synthesis of SRH (see Scheme 2.9). 
 
To obtain target compound 15, we returned to earlier stages in the synthesis of original 
target 14b (Scheme 3.3) and initially planned to complete two conversions: (1) PMP (of 
14b) to Boc (as in 3b) and (2) EtO‐  (also of 14b) to tBuO‐  (also as in 3b) through 
several steps (Scheme 3.4). The first conversion (PMPBoc) began at intermediate 11a 
(Scheme 3.5). Protection of the free hydroxyl group of 11a with TBDMS was necessary 
due to the highly oxidative conditions required for the removal of the PMP protection. 
Silyl ether 16 was obtained successfully with a good yield of 80%. Although this 
protection proceeded easily, the deprotection of the PMP group was unsuccessful using 
numerous oxidizing reagents, including ceric ammonium nitrate (CAN)
34
, phenyl 
iodoacetate (PhI(OAc)2)
35
, trichloroisocyanuric acid (TCCA) and periodic acid (H5IO6)
36
. 
Attempts to remove the PMP from intermediate 11a prior to silyl protection by the same 
oxidative conditions had also failed. Thus, the sequence reported in Scheme 3.5 was 
abandoned. 
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Scheme 3.5. Proposed approach to the replacement of two protecting  groups . The fo llowing 
oxidizing reagents were utilized for the deprotection of PMP group: CAN, PhI(OAc)2, TCCA and 
H5IO6.
34-36
 
 
The synthesis of 11a by reduction of 10 (Scheme 3.3), as already established in the 
synthesis of modified HCys 14b, interestingly gave a different product here under the 
exact same reduction conditions.  Whereas 11a was an oil in the original synthesis, this 
new product was a solid. Compound 11a was not observed in this product by 
1
H NMR. 
The structure for this new product 11b (as characterized by 
1
H and 
13
C NMR and IR) and 
a possible explanation of formation are shown in Scheme 3.5. We also attempted to 
deprotect the PMP group from 11b by the same oxidative conditions mentioned above, 
with the hope that we could later run a ring-opening reaction and reutilize this unexpected 
compound 11b to continue the synthesis. However, the removal of PMP group from 11b 
was likewise unsuccessful. 
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Scheme 3.6. Mechanism of the formation of unexpected 5-membered ring product 11b. 
 
Since the removal of the PMP protecting group proved an insurmountable problem, the 
use of an alternate imine (in place of compound 9) for the Mannich reaction, ideally 
having the Boc protecting group in place of PMP from the very beginning, was proposed. 
 
3.3 Third Attempt – An Alternate Imine Synthetic Pathway 
 
Realizing the difficulty of removal of the PMP protecting group, another synthetic 
pathway was proposed to utilize an alternate imine (to replace compound 9) having the 
desirable Boc protecting group in place of PMP from the start. The synthesis of imine 17 
with Boc protect on was approached by Armstrong’s report in 2005 as shown in Scheme 
3.6.
37
 It was anticipated that this new imine could react stereospecifically with simple 
aldehyde donors to produce the desired Mannich products under the presence of L-
proline, as demonstrated previously.
29
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Scheme 3.7. Mannich reaction carried with an alternate imine. 
 
However, imine 17 was reported to be quite unstable even at low temperature of -78
o
C 
and therefore needed to be used for the next step immediately, without purification.
37
 It 
was difficult to characterize compound 17 from the 
1
H NMR spectrum of the crude 
product. Next, a Mannich reaction with propionaldehyde employing similar reaction 
conditions as applied previously was unsuccessful. Since we could not determine whether 
we obtained desired imine 17 or not in the earlier step, we cannot identify which step was 
the reason for the failure of the Mannich reaction under these conditions.  
 
3.4 Fourth Attempt – Alkyl Iodine Pathway 
 
At this point, an alternative approach the stereochemical product bearing the novel “R” 
group substituent was needed. The reasons are as follows: (1) The product from the 
Mannich reaction is unpredictable; we could obtain two different products (11a and/or 
11b) through the same reaction. (2) The PMP group of the imine 9 that is utilized in 
common asymmetric Mannich reactions is intransigent to deprotection. Both cases 
prevent the later steps required for the synthesis of SRH HCys-C3 analogs. Therefore, 
another synthetic method avoiding using the Mannich reaction to produce the compound 
substituted at the C3 position was required. 
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In light of Wolf’s report on a general synthetic methodology for preparation of lactams38, 
we proposed the following synthetic pathway towards the synthesis of C3-substituted 
HCys (shown in Scheme 3.8). Beginning with the commercially available L-aspartic acid, 
selective protection of the two carboxyl groups into β-methyl ester and α-tert-butyl ester, 
and then amino group to tert-butyl carbamate would produce the fully protected aspartic 
acid 19. The next step is key step in this proposed synthesis: reaction with methyl iodine 
to accomplish methyl substitution at the C3 position. Then, standard reduction with 
DIBAL would afford an alcohol that is similar to compound 11a. By following 
previously-successful steps, that alcohol could be converted to a thiol having the same 
protecting groups as the homocysteine moiety used in the successful synthesis of SRH 
(Scheme 2.7).  
 
Scheme  
 
 
3.8. Synthesis of modified homocysteine moiety inspired by Wolf et al.
37 
This plan failed at  the 
key step (third step above) of reaction with methyl iodine. 
 
The L-aspartic acid was fully protected as compound 19 through 2 steps. Compounds 18 
and 19 were successfully characterized by NMR with the excellent yields of 78% and 
84%, respectively. However, the reaction between the fully protected L-aspartic acid 19 
and the methyl iodine was unsuccessful resulted in decomposition. The possible reason 
for this failure may be protecting groups Boc and t-Bu, which perhaps shield the C3 
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position of compound 19 from substitution. Also, different bases (i.e. KH, LDA) could be 
tried for the crucial reaction with methyl iodine, in place of KHMDS. 
 
Overall, all attempts tried towards the synthesis of SRH C3 analogs were unsuccessful 
due to different reasons. However, the information obtained could be helpful for the 
future synthesis of HCys-C4 analogs or HCys-C3/C4 analogs proposed in our lab. These 
SRH analogs are also modified at the homocysteine moiety and designed to maintain as 
many binding contacts between SRH and monomer A of LuxS as possible, yet prevent 
the association with monomer B that carries the catalytic Cys84 residue. 
 
Figure 3.4. Other proposed SRH analogs as potential  LuxS inhibitors in our lab. Introduction 
of steric bulk at positions 3 and/or 4 of SRH as shown may impede the approach of monomer B 
while maintaining tight binding with monomer A. 
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Chapter 4. Appendices 
 
4.1 TLC Analysis 
 
In the TLC analysis of the crude product from a reaction (shown in Figure 4.1.a), it was 
expected if there was only one new spot shown on the TLC plate, that would mean 
coupling reaction likely succeeded. Alternatively, if there were still two separated spots 
with same Rf values as starting materials Reagent 1 (R1) and Reagent 2 (R2), that would 
mean the two starting materials had not reacted with each other. Finally, if several new 
spots other than starting materials R1 and R2 showed on the TLC plate, then the reaction 
was possibly decomposed. Our TLC plate (Figure 4.1.b) for the crude product of 
Mitsunobu-type coupling reaction (Scheme 2.2) showed several new spots with different 
Rf values from compound 1 and 2a, which suggested a decomposition happened. 
Figure 4.1. (a) Three possible results of TLC analysis (under same solvent system). R1 – 
Reagent 1; R2 – Reagent 2;  P – Product. (b) TLC results of Mitsunobu-type coupling reaction. 
1 – Compound 1; 2a – Compound 2a; P’ – Prodouct from attempted coupling reaction. 
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4.2 
1
H NMR Characterization of (+/-) SRHTFA Salt 6 
 
 
Figure 4.2. 
1
H NMR Characterization of (+/-) SRHTFA salt 6. The new peaks between δ 2.5 ~ 
3.0 ppm suggested the formation of S-C bond. 
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4.3 Re-characterization of (+/-) SRHTFA Salt 6 after C18 Column Purification 
 
 
Figure 4.3. Re-characterization of (+/-) SRHTFA salt 6. After C18 column purification, the 
compound has been re-characterized showing same chemical shifts with previously-characterized. 
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4.4 
1
H NMR Characterization of Thiol to Disulfide  Conversion 
 
 
 
 
 
Scheme 4.1. Oxidation of free thiol to disulfide. 
 
The purified thiol 14b from silica gel column chromatography was prone to be oxidized 
into disulfide. This conversion from free thiol 14b to disulfide 14a was characterized by 
1
H NMR as shown in Figure 7. First, a sample of pure free thiol 14b was examined by 
1
H 
NMR (Figure 2.3.A. proton peak (a) indicates the –OCH3 group). After being exposed to 
air for 3 ~ 4 days, the same thiol sample in the same NMR tube was re-characterized by 
1
H NMR. Figure 2.3.B shows the splitting of -OCH3 peak into (a) and (b). Peak (a) 
indicates the existence of free thiol, while the peak (b) suggests the formation of 
disulfide. Thus, it was concluded that this free thiol is not stable. 
O
O
NH
H3CO
SH
O
O
NH
H3CO
S 2[ O ]
open to air
14a14b
2
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(A) 
(B)  
Figure 4.4. (A) 
1
H NMR of thiol; (B) 
1
H NMR shows the conversion of free thiol to disulfide. 
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4.5 Biological Evaluation of Chemically – Synthesized SRH 
 
 
Figure 4.5. Ellman’s assay for LuxS activity. Catalyzed by the LuxS enzyme, SRH converts to 
DPD and HCys. HCys reacts with DTNB to give a disulfide conjugate and a byproduct 2-nitro-5-
thiobenzoate (NTB-). NTB- could ionize to NTB2- in aqueous solution. This yellow NTB2- ion can 
be measured at λmax = 412 nm to determine the activity of LuxS. 
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(A) 
Enzyme KM(μM) Vmax (μmol/s) kcat(s
-1
) 
Co-Bs-LuxS-HT 
House-purified 
2.1±1.4 1.1×10
-5
 0.014±0.002 
Co-Bs-LuxS-HT 
(by Pei et al.)
47
 
2.3±0.5 2.8×10
-5
 0.035±0.003 
 (B) 
Figure 4.6. Michaelis Menten Curve and Comparison of Kinetic Constants. (A) Michaelis-
Menten curve for Co -Bs LuxS-HT enzyme purified in our lab conditions  using chemically -
synthesized SRH as substrate. Red dotted lines show the values of kinetic constants on the curve . 
(B) Kinetic constants comparing  in-house LuxS activity assay to reported values of the two  Co -
BsLuxS-HT enzymes. The KM values for both enzymes are almost same confirming that our 
enzyme is equally active.
45
(Graph and data by courtesy of Richa Gupta.) 
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Chapter 5. Experimental Section 
 
5.1 General Information 
 
Unless otherwise indicated, all reagents were of research grade or finer and were used 
without further purification. Methanol was distilled at reflux from magnesium and iodine. 
Anhydrous solvents dichloromethane, ethyl ether, toluene and tetrahydrofuran (THF) 
were obtained from a glass contour solvent system (SG Water USA, LLC). Air- and 
water-sensitive reactions were carried out in oven-dried glassware under a dry argon 
atmosphere. Flash column chromatography was carried out with Sorbent Technologies 60 
Å (500-600 Mesh) silica gel, applying the chromatographic technique reported by W. 
Clark Still (1978).
39
 Thin Layer Chromatography (TLC) was performed using Sorbent 
Technologies silica gel UV254 (200 μm layer) plates. NMR spectra were acquired on a 
Varian – NMR 500 MHz instrument. Chemical shift values are expressed in ppm and 
residual solvent signals were used as references: CDCl3 (7.26 ppm for 
1
H and 77.16 ppm 
for 
13
C), D2O (4.79 ppm for 
1
H). IR data was obtained through PerkinElmer Frontier IR 
Spectrometer. 
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5.2 Experimental Procedures and Data 
 
 
 
 
Methyl 2,3-O-isopropylidene-D-ribofuranoside (1) Modification of published 
procedure.
40 
D-ribose (3.49 g, 23.02 mmol) was dissolved in 1:1 MeOH : acetone (30 
mL) and allowed to stir at room temperature. Concentrated HCl (12.1 M, 0.5 mL) was 
added in one portion via pipet. The reaction mixture was heated at reflux for 1.5 h. The 
solution was cooled to room temperature and pyridine was added dropwise until the 
mixture was neutral by pH paper. The solution was concentrated by rotary evaporation to 
a thick yellow oil and then redissolved in a mixture of EtOAc (20 mL) and water (50 
mL). The product was extracted with EtOAc (3 × 25 mL). The organic fractions were 
combined and washed with saturated aqueous copper sulfate (50 mL), then water (50 
mL), and finally with brine (50 mL). The organic fraction was dried over MgSO4, filtered 
and concentrated to a pale blue oil. Silica gel column chromatography with 2:1 EtOAc : 
hexanes afforded 1 as a thick colorless oil (3.10 g, 15.19 mmol, 66%). TLC: Rf = 0.54 in 
2:1 EtOAc : hexanes. 
1
H NMR (500 MHz, CDCl3): δ 4.97 (s, H1), 4.83 (d, J = 6.0 Hz, 
H2), 4.58 (d, J = 6.0 Hz, H3), 4.43 (t, J = 2.3 Hz, H4), 3.70 (m, H5), 3.61 (m, H5’), 3.43 (s, 
OCH3), 3.23 (dd, J = 10.6, 2.6 Hz, OH, disappeared upon D2O exchange), 1.48 (s, H7), 
1.32 (s, H6).
 13
C NMR (126 MHz, CDCl3): δ 24.87, 26.51, 55.67, 64.18, 81.64, 85.99, 
88.55, 110.16, 112.27. According with the GC-analysis from previous report, the product 
is a mixture of the anomeric methyl 2,3-O-isopropylidene-D-ribofuranoside, in which the 
β-anomer predominates.40 
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N,N’-Bis(tert-butoxycarbonyl)-L-homocystine methyl ester (2a) Modification of 
published procedure.
40 
SOCl2 (1 mL) was added dropwise to methanol (10 mL, distilled) 
at 0 °C. Upon complete addition, the mixture was stirred for 10 min. L-homocystine (268 
mg, 1.00 mmol) was then added to the solution at 0 °C. The reaction mixture was stirred 
at room temperature for 72 h under argon and then concentrated by rotary evaporation at 
40 °C. Dioxane (2 mL) and water (1 mL) were added to the residue. The pH of the 
reaction mixture was adjusted to approximately 9 with 10% aqueous Na2CO3 solution. 
After the reaction mixture was cooled to 0 °C,  di-tert-butyldicarbonate (1.00 g, 4.58 
mmol) was added. The reaction mixture was stirred overnight at room temperature and 
the pH of the reaction mixture was maintained around 9 by adding 10% aqueous Na2CO3 
solution periodically. Then the reaction mixture was extracted with CHCl3 (10 mL × 3) 
and concentrated by rotary evaporation. The residue was redissolved in EtOAc (50 mL), 
washed with saturated aqueous NaHCO3 solution (15 mL × 3) and brine (30 mL), dried 
over MgSO4, filtered and concentrated. Silica gel column chromatography with 2:1 
hexanes : EtOAc afforded 2a as a white crystal (437 mg, 0.88 mmol, 88%). TLC: Rf = 
0.34 in 2:1 hexanes : EtOAc. 
1
H NMR (500 MHz, CDCl3): δ 5.20 (d, J = 8.7 Hz, NH), 
4.33 (m, H1), 3.69 (s, OCH3), 2.65 (t, J = 7.4 Hz, H3), 2.18 (m, H2), 1.94 (m, H2’), 1.37 (s, 
H4). 
13
C NMR (126 MHz, CDCl3): δ 28.30, 32.47, 34.52, 52.44, 52.53, 80.00, 155.34, 
172.62. Previously characterized.
40 
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N,N’-Bis(tert-butoxycarbonyl)-L-homocystine di(tert-butyl) ester (2b) Modification 
of published procedure.
33, 41
 To a solution of L-homocystine (268 mg, 1.00 mmol) in the 
mixture of 10% aqueous Na2CO3 solution (9 mL) and dioxane (8 mL) was added (Boc)2O 
(0.48 g, 2.20 mmol) at 0 °C. The mixture was stirred overnight at room temperature. The 
solution was adjusted to pH 4 with 10% aqueous citric acid solution and extracted with 
EtOAc (3 × 10 mL). The organic fractions were combined, washed with brine (20 mL), 
dried over MgSO4, and concentrated by rotary evaporation. The residual solid was 
redissolved in dichloromethane (10 mL) followed by the addition of tert-butyl-2,2,2-
trichloroacetimidate (1.15 g, 5.00 mmol) under argon. After overnight stirring at room 
temperature, the solvent was removed by rotary evaporation. Silica gel column 
chromatography with 4:1 hexanes : EtOAc afforded 2b as a colorless oil (523 mg, 0.90 
mmol, 90%, the oil phase converted to white solid when temperature was down to 8 °C). 
TLC: Rf = 0.33 in 4:1 hexanes : EtOAc. 
1
H NMR (500 MHz, CDCl3): δ 5.10 (d, J = 7.6 
Hz, NH), 4.24 (m, H1), 2.69 (m, H3), 2.20 (m, H2), 1.98 (m, H2’), 1.47 (s, H4), 1.44 (s, H5). 
13
C NMR (126 MHz, CDCl3): δ 28.16, 28.47, 33.05, 34.69, 53.36, 79.98, 82.41, 155.48, 
171.34. Previously characterized.
33, 41
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N-tert-Butoxycarbonyl-L-homocysteine methyl ester (3a) Modification of published 
procedure.
33, 41
 To a solution of 2a (0.51 g, 1.03 mmol) in DMF (10 mL) was added water 
(1 mL) and tri-n-butylphosphine (292 μL, 236 mg, 1.13 mmol) and the mixture was 
stirred at room temperature overnight under argon (TLC [3:1 hexanes : EtOAc] showed 
the conversion of disulfide 2a [Rf 0.31] into thiol 3a [Rf 0.46]). The reaction mixture was 
quenched with water (100 mL) and thoroughly extracted with EtOAc (3 × 50 mL). The 
organic fractions were combined and washed with brine (2 × 50 mL), dried over MgSO4, 
filtered and concentrated by rotary evaporation. Silica gel column chromatography with 
3:1 hexanes : EtOAc afforded 3a as a thick colorless oil (513 mg, 2.06 mmol, quantitative 
yield). TLC: Rf = 0.46 in 3:1 hexanes : EtOAc. 
1
H NMR (500 MHz, CDCl3): δ 5.07 (d, J 
= 6.9 Hz, NH), 4.45 (m, H1), 3.75 (s, OCH3), 2.59 (m, H3), 2.10 (t, J = 6.7 Hz, H2), 1.93 
(m, H2’), 1.56 (t, J = 8.0 Hz, SH), 1.44 (s, H4). 
13
C NMR (126 MHz, CDCl3): δ 20.85, 
28.44, 37.39, 52.42, 52.59, 80.32, 155.94, 173.07. Previously characterized.
42
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N-tert-Butoxycarbonyl-L-homocysteine tert-butyl ester (3b) Modification of 
published procedure.
33, 41
 Treatment of 2b (639 mg, 1.10 mmol) with tri-n-butylphosphine 
(313 μL, 253 mg, 1.21 mmol) in the mixture of DMF (10 mL) and water (1 mL), as 
described for 3a, followed by silica gel column chromatography with 4:1 hexanes : 
EtOAc afforded 3b as a thick colorless oil (641 mg, 2.20 mmol, quantitative yield). TLC 
(4:1 hexanes : EtOAc) showed the conversion of disulfide 2b (Rf 0.33) into thiol 3b (R f 
0.50).
 1
H NMR (500 MHz, CDCl3): δ 5.05 (d, J = 6.7 Hz, NH), 4.31 (m, H1), 2.58 (m, 
H3), 2.06 (m, H2), 1.95 (m, H2’), 1.58 (t, J = 4.9 Hz, SH), 1.47 (s, H4), 1.45 (s, H5). 
13
C 
NMR (126 MHz, CDCl3): δ 20.86, 28.10, 28.44, 37.69, 53.04, 79.90, 82.28, 155.47, 
171.46. Previously characterized.
33, 41
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Methyl 2,3-O-isopropylidene-5-O-methylsulfonyl-D-ribofuranoside (4a) Modification 
of published procedure.
23
 To a stirred solution of 1 (0.61 g, 3.00 mmol) in anhydrous 
CH2Cl2 (100 mL) was added triethylamine (1.25 mL, 0.91 g, 9.00 mmol) and mesyl 
chloride (350 μL, 0.51 g, 4.50 mmol) at 0 oC under argon. After stirring for 30 min, the 
reaction mixture was partitioned (NaHCO3/H2O/CHCl3), and the organic layer was 
washed by brine, dried over MgSO4, filtered and concentrated by rotary evaporation to 
yield 4a as a white crystal (0.84 g, 2.97 mmol, 99%) of sufficient purity to be used for the 
formation of compound 5. 
1
H NMR (500 MHz, CDCl3): δ 4.97 (s, H1), 4.68 (d, J = 5.9 
Hz, H2), 4.59 (d, J = 5.9 Hz, H3), 4.39 (t, J = 2.8 Hz, H4), 4.18 (dd, J = 7.2, 1.7 Hz, H5), 
3.33 (s, OCH3), 3.05 (s, H8), 1.46 (s, H7), 1.30 (s, H6). 
13
C NMR (126 MHz, CDCl3): δ 
25.01, 26.49, 37.83, 55.33, 68.61, 81.45, 83.90, 85.02, 109.68, 112.93. 
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Methyl 2,3-O-isopropylidene-5-O-p-toluenesulfonyl-D-ribofuranoside (4b) 
Modification of published procedure.
23
 TsCl (191 mg, 1.00 mmol) was added to a stirred 
solution of 1 (102 mg, 0.50 mmol) in pyridine (2 mL) at 0 
o
C under argon. After stirring 
for 24 h at room temperature, pyridine was evaporated/coevaporated with toluene (3 × 2 
mL) and the residue was dissolved in EtOAc (20 mL) and washed with saturated aqueous 
NaHCO3 solution (2 × 10 mL)  and brine (20 mL). The organic layer was dried over 
MgSO4, filtered, concentrated and recrystallized by EtOH (30 mL) to give 4b (176 mg, 
0.49 mmol, 98%) as a white crystal. 
1
H NMR (500 MHz, CDCl3): δ 7.81 (d, J = 8.3 Hz, 
H8), 7.36 (d, J = 7.9 Hz, H9), 4.93 (s, H1), 4.60 (d, J = 5.9 Hz, H2), 4.53 (d, J = 5.9 Hz, 
H3), 4.31 (t, J = 7.2 Hz, H4), 4.02 (dd, J = 7.2, 2.8 Hz, H5), 3.24 (s, OCH3), 2.46 (s, H10), 
1.45 (s, H7), 1.29 (s, H6). 
13
C NMR (126 MHz, CDCl3): δ 21.61, 24.85, 26.32, 54.98, 
69.34, 81.33, 83.60, 84.86, 109.44, 112.66, 127.94, 129.94, 132.74, 145.12. 
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S-(Methyl-2,3-O-isopropylidene-D-ribofuranoside) homocysteine (5) Modification of 
published procedure.
23
 Compound 4a (51 mg, 0.18 mmol) was added to 1 M NaOH/ H2O 
(5 mL) and the reaction mixture was stirred under argon. D/L-Homocysteine (37 mg, 0.27 
mmol) was then added, and the suspension was heated to 60 
o
C. After 12 h, the reaction 
mixture was cooled to room temperature, neutralized with dilute HCl (0.5 M) to pH ~ 7 
and washed with EtOAc (3 × 5 mL). The aqueous layer was evaporated by rotary 
evaporation at 50 
o
C to give 5 as a white solid. (Yield was not determined since it was not 
purified.)
 1
H NMR (500 MHz, D2O): δ 5.21 (s, H1), 5.00 (dd, J = 5.9, 2.8 Hz, H2), 4.90 (d, 
J = 5.9 Hz, H3), 4.43 (d, J = 1.4 Hz, H4), 3.97 (m, H10), 3.51 (s, OCH3), 3.00 – 2.82 (m, 
H5, 8), 2.35 – 2.19 (m, H9), 1.62 (s, H7), 1.48 (s, H6). 
13
C NMR (126 MHz, D2O): δ 23.85, 
25.40, 27.03, 30.56, 34.68, 53.88, 55.11, 82.96, 84.45, 85.36, 108.85, 113.17, 174.07. 
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S-(Methyl-2,3-O-isopropylidene-D-ribofuranoside)-N-(tert-butoxycarbonyl)-L-
homocysteine tert-butyl ester (7) Modification of published procedure.
23
 Method A 
(used purified 3b): To a solution of purified 3b (1.08 g, 3.70 mmol) in DMF (15 mL) was 
added BuLi (1.6 M in hexane, 2.32 mL, 3.71 mmol) at 0 
o
C under argon. After stirring for 
10 min, a solution of tosylate 4b (0.66 g, 1.85 mmol) was dissolved in DMF (10 mL) was 
added. The mixture was stirred for overnight at room temperature, diluted with EtOAc 
(75 mL), washed with H2O (50 mL) and brine (25 mL). The organic layer was dried over 
MgSO4 and concentrated by rotary evaporation. The residue was dissolved in THF (3 
mL), concentrated H2SO4 (18.0 M, 2 μL) and H2O (2 μL) were added at 0 
o
C. The 
mixture was stirred for 1 h at 0 
o
C and then partitioned between EtOAc (100 mL) and 5% 
NaHCO3 solution (40 mL). The organic layer was collected, washed with H2O (30 mL) 
and brine (30 mL), dried over MgSO4 and concentrated. Silica gel chromatography with 
1:3 EtOAc : hexane afforded protected homocysteine 7 (0.51 g, 1.06 mmol, 70%) as a 
colorless oil. TLC: Rf  = 0.34 in 1:3 EtOAc : hexane.
 1
H NMR (500 MHz, CDCl3): δ 5.09 
(d, J = 8.4 Hz, NH), 4.95 (s, H1), 4.68 (d, J = 6.0 Hz, H2), 4.58 (d, J = 5.9 Hz, H3), 4.29 – 
4.18 (m, H10, 4), 3.33 (s, OCH3), 2.74 (dd, J = 13.5, 6.1 Hz, H5), 2.60 – 2.52 (m, H5’ , 8), 
2.06 (s, H9), 1.91 – 1.83 (m, H9’), 1.46 (s, H7, 12), 1.43 (s, H11), 1.30 (s, H6). 
13
C NMR (126 
MHz, CDCl3): δ 25.09, 26.56, 27.87, 28.13, 28.45, 33.25, 35.72, 53.51, 55.07, 55.08, 
82.33, 83.45, 85.39, 85.89, 109.71, 112.57, 155.45, 171.35. 
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S-(Methyl-2,3-O-isopropylidene-D-ribofuranoside)-N-(tert-butoxycarbonyl)-L-
homocysteine tert-butyl ester (7) Modification of published procedure.
23, 33, 41
 Method B 
(used crude 3b): To a solution of 2b (581 mg, 1.00 mmol) in DMF (10 mL) was added 
water (1 mL) and tri-n-butylphosphine (285 μL, 230 mg, 1.10 mmol) and the mixture was 
stirred at room temperature overnight under argon (TLC [4:1 hexanes : EtOAc] showed 
the completed conversion of disulfide 2b [Rf 0.33] into thiol 3b [Rf 0.50]). The reaction 
mixture was quenched with water (100 mL) and thoroughly extracted with EtOAc (3 × 50 
mL). The organic fractions were combined and washed with brine (2 × 50 mL), dried 
over MgSO4, filtered and concentrated by rotary evaporation. Without further 
purification, the residue was redissolved in DMF (8 mL) was added BuLi (1.6 M in 
hexane, 1.25 mL, 2.01 mmol) at 0 
o
C under argon. After stirring for 10 min, a solution of 
tosylate 4b (0.36 g, 1.00 mmol) was dissolved in DMF (5.5 mL) was added. The mixture 
was stirred for overnight at room temperature, diluted with EtOAc (50 mL), washed with 
H2O (30 mL) and brine (20 mL). The organic layer was dried over MgSO4 and 
concentrated by rotary evaporation. The residue was dissolved in THF (1.5 mL), 
concentrated H2SO4 (18.0 M, 1 μL) and H2O (1 μL) were added at 0 
o
C. The mixture was 
stirred for 1 h at 0 
o
C and then partitioned between EtOAc (50 mL) and 5% NaHCO3 
solution (20 mL). The organic layer was collected, washed with H2O (15 mL) and brine 
(15 mL), dried over MgSO4 and concentrated. Silica gel chromatography with 1:3 EtOAc 
: hexane afforded protected homocysteine 7 (0.31 g, 0.64 mmol, 64%) as a colorless oil. 
TLC and NMR data were same as previously characterized in Method A. 
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S-Ribosyl-L-homocysteine (8) Modification of published procedure.
23
 Compound 7 (148 
mg, 0.31 mmol) was added into the mixture of TFA (4 mL), water (0.5 mL) and anisole 
(0.5 mL) at 0 
o
C. After stirring for 6 h at room temperature, the volatile solvents were 
removed by rotary evaporation, and the residue was dissolved in H2O (3 mL) and washed 
with CH2Cl2 (3 × 2 mL). The aqueous solution was lyophilized to give the desired SRH 8 
as a trifluoroacetate salt (111 mg, 94%). 
1
H NMR (500 MHz, D2O): δ 5.23 (d, J = 4.1 Hz, 
H1), 5.08 (d, J = 1.2Hz, H1), 4.11 – 3.84 (m, H2, 3, 4, 8), 2.84 – 2.58 (m, H5, 6), 2.23 – 2.00 
(m, H7). Previously characterized.
40
 The ratio of -form and -form was 1 to 2, 
determined from 
1
H NMR integration of the anomeric proton peaks (-form at 5.23 ppm, 
J = 4.1 Hz; and -form at 5.08 ppm, J = 1.2Hz). 
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Ethyl (E)-2-(p-methoxyphenylimino) acetate (9) Modification of published 
procedure.
28 
A mixture of ethyl glyoxylate (polymer form 45-50% in toluene, 1 mL, ~ 4.5 
mmol), p-anisidine (554 mg, 4.50 mmol), and molecular sieves 4 Å (5 g) in anhydrous 
CH2Cl2 (25 mL) was stirred at room temperature overnight. After filtration through celite, 
the solution was concentrated by rotary evaporation to afford the imine 9 as thick dark 
brown oil (914 mg, 4.40 mmol, 98%) of sufficient purity to be used for the Mannich 
reaction.  
1
H NMR (500 MHz, CDCl3): δ 7.93 (s, H4), 7.36 (d, J = 8.9 Hz, H6), 6.93 (d, J 
= 8.9 Hz, H5), 4.41 (q, J = 7.1 Hz, H2), 3.84 (s, OCH3), 1.40 (t, J = 7.1 Hz, H1). 
13
C NMR 
(126 MHz, CDCl3): δ 14.38, 55.67, 62.06, 114.69, 123.74, 141.55, 148.05, 160.66, 
163.77. Previously characterized.
28
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Ethyl (2S,3S)-3-formyl-2-(p-methoxyphenylamino)-butanoate (10) Modification of 
published procedure.
29 
To a stirred solution of imine 9 (104 mg, 0.50 mmol) in DMSO (1 
mL) was added L-proline (17 mg, 0.15 mmol) followed by the addition of 
propionaldehyde (58 mg, 72 μL, 1.00 mmol) in one portion. The reaction mixture was 
stirred at room temperature for 3 h (TLC showed the completion of reaction). The 
saturated aqueous NH4Cl solution (10 mL) and EtOAc (10 mL) were added with vigorous 
stirring, the layers were separated and the organic phase was washed with water, dried 
over MgSO4, concentrated by rotary evaporation. Silica gel column chromatography with 
3:1 hexanes : EtOAc afforded 10 as a thick yellow oil (65 mg, 0.25 mmol, 49%). TLC: R f 
= 0.26 in 3:1 hexanes : EtOAc.
 1
H NMR (500 MHz, CDCl3): δ 9.73 (s, CHO), 6.78 (m, 
H6), 6.68 (m, H5), 4.45 (dd, J = 10.0, 4.4 Hz, H3), 4.20 (q, J = 7.0 Hz, H2), 3.91 (d, J = 
10.2 Hz, NH), 3.74 (s, OCH3), 2.87 (m, H4), 1.28 – 1.22 (m, H1, 7). 
13
C NMR (126 MHz, 
CDCl3): δ 9.27, 14.33, 48.41, 55.81, 58.73, 61.73, 114.99, 116.53, 140.64, 153.64, 
172.48, 201.91. Previously characterized.
30  
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Ethyl (2S,3S)-4-hydroxy-2-(p-methoxyphenylamino)-3-methyl-butanoate (11a) 
Modification of published procedure.
30
 To a solution of compound 10 (60 mg, 0.23 
mmol) in anhydrous ethyl ether (2 mL) was added NaBH4 (44 mg, 1.15 mmol) at 0 
o
C. 
After 30 min, the saturated aqueous NH4Cl solution was added until no air bubbles 
formed. The reaction mixture was extracted with EtOAc (3 × 10 mL). The organic 
fractions were combined and washed with brine, dried over MgSO4 and concentrated by 
rotary evaporation. Silica gel column chromatography with 2:1 hexanes : EtOAc afforded 
11a as a thick yellow oil (59 mg, 0.22 mmol, 96%). TLC: Rf = 0.29 in 2:1 hexanes : 
EtOAc. 
1
H NMR (500 MHz, CDCl3): δ 6.78 (m, H6), 6.72 (m, H5), 4.18 (m, H2, 3), 4.02 (s, 
NH), 3.74 (s, OCH3), 3.72 – 3.62 (m, H8), 2.39 (s, OH), 2.24 (m, H4), 1.24 (t, J = 7.1 Hz, 
H1), 1.00 (d, J = 7.1 Hz, H7). 
13
C NMR (126 MHz, CDCl3): δ 11.90, 14.40, 38.28, 55.84, 
61.21, 61.30, 65.97, 114.99, 116.62, 141.53, 153.49, 174.01. 
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(3S,4R)-3-(p-methoxyphenylamino)-4-methyl-dihydro-2(3H)-furanone (11b) 
Modification of published procedure.
30
 Treatment of 10 (1.34 g, 5.05 mmol) with NaBH4 
(0.96 g, 25.25 mmol) in ethyl ether (40 mL), as described for 11a, followed by silica gel 
column chromatography with 2:1 hexanes : EtOAc afforded another product 11b as a 
yellow solid (0.96 g, 4.34 mmol, 86%). TLC: Rf = 0.33 in 2:1 hexanes : EtOAc. 
Compound 11a was not observed in this manner.
 1
H NMR (500 MHz, CDCl3): δ 6.77 (m, 
H6), 6.68 (m, H5), 4.40 (dd, J = 9.1, 7.6 Hz, H3), 3.84 (m, NH, H1), 3.74 (s, OCH3), 3.72 
(d, J = 2.4 Hz, H1’), 2.48 (tt, J = 10.5, 6.8 Hz, H2), 1.24 (d, J = 6.7 Hz, H4). 
13
C NMR (126 
MHz, CDCl3): δ 15.34, 38.94, 55.78, 61.03, 71.26, 114.90, 115.73, 140.78, 153.28, 
176.79. IR (ATR): 3391 (NH), 2963, 1763 (C=O), 1513, 1234, 1030, 801 cm
-1
.  
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Ethyl (2S,3S)-2-(p-methoxyphenylamino)-3-methyl-4-methylsulfonyl-butanoate (12) 
Modification of published procedure.
43 
To a stirred solution of 11a (99 mg, 0.37 mmol) in 
anhydrous CH2Cl2 (10 mL) was added triethylamine (154 μL, 112 mg, 1.11 mmol) and 
mesyl chloride (44 μL, 64 mg, 0.56 mmol) at 0 oC under argon. After stirring overnight, 
the reaction mixture was partitioned (NaHCO3/H2O/CH2Cl2), and the organic layer was 
washed by brine, dried over MgSO4, filtered and concentrated by rotary evaporation to 
yield 12 as a dark yellow oil (120 mg, 0.35 mmol, 94%) of sufficient purity to be used for 
the formation of compound 13. 
1
H NMR (500 MHz, CDCl3): δ 6.76 (d, J = 8.7 Hz, H6), 
6.67 (d, J = 8.8 Hz, H5), 4.25 (dd, J = 9.7, 8.5 Hz, H3), 4.22 – 4.12 (m, H2,8), 3.73 (s, 
OCH3), 2.97 (s, H9), 2.53 (m, H4), 1.25 (t, J = 7.1 Hz, H1), 0.99 (d, J = 7.0 Hz, H7). 
13
C 
NMR (126 MHz, CDCl3): δ 11.40, 14.32, 36.15, 37.27, 55.77, 58.87, 61.55, 71.32, 
114.99, 116.32, 141.30, 153.43, 173.18. 
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Ethyl (2S,3S)-2-(p-methoxyphenylamino)-3-methyl-4-thioacetyl-butanoate (13) 
Modification of published procedure.
31 
To a solution of compound 12 (0.35 g, 1.01 mmol) 
in DMF (10 mL) was added potassium thioacetate (0.51 g, 4.40 mmol) at 0 
o
C under 
argon. The reaction mixture was stirred for 1 d at room temperature. The solvent was 
removed by rotary evaporation. The residue was dissolved in the mixture of EtOAc (30 
mL) and water (30 mL). The organic layer was collected and washed by water, dried over 
MgSO4 and concentrated by rotary evaporation. Silica gel column chromatography with 
3:1 hexanes : EtOAc afforded 13 as a brown oil (166 mg, 0.51 mmol, 50%). TLC: R f = 
0.46 in 3:1 hexanes : EtOAc. 
1
H NMR (500 MHz, CDCl3): δ 6.77 (d, J = 8.9 Hz, H6), 
6.65 (d, J = 8.9 Hz, H5), 4.20 – 4.10 (m, H2), 4.04 (d, J = 4.1 Hz, H3), 3.74 (s, OCH3), 
3.06 (m, H8), 2.93 (m, H8’), 2.36 (s, H9), 2.22 (qd, J = 6.9, 3.9 Hz, H4), 1.24 (t, J = 7.1 Hz, 
H1), 1.03 (d, J = 7.0 Hz, H7). 
13
C NMR (126 MHz, CDCl3): δ 195.50, 173.56, 153.22, 
141.58, 116.16, 114.97, 61.48, 61.29, 55.82, 36.99, 32.91, 30.80, 14.86, 14.38.  
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Ethyl (2S,3S)-2-(p-methoxyphenylamino)-3-methyl-4-thiol-butanoate (14b) 
Modification of published procedure.
32
 To a stirred solution of Compound 13 (0.12 g, 
0.37 mmol) in distilled MeOH (10 mL) was added sodium thiomethoxide (0.41 g, 0.56 
mmol) at room temperature under argon. After 30 min, the reaction was quenched with 
0.1 M HCl (10 mL), extracted with CH2Cl2 (3 × 10 mL). The organic fractions were 
combined and washed with brine, dried over MgSO4, filtered and concentrated by rotary 
evaporation. Then treatment of the residue with tri-n-butylphosphine (96 μL, 77 mg, 0.37 
mmol) in the mixture of DMF (3 mL) and water (0.3 mL), as described for compound 3a, 
followed by silica gel column chromatography with 2:1 hexanes : EtOAc afforded 14b as 
a light yellow oil (68 mg, 0.24 mmol, 65%). TLC: Rf = 0.56 in 2:1 hexanes : EtOAc. 
1
H 
NMR (500 MHz, CDCl3): δ 6.77 (d, J = 8.9 Hz, H6), 6.72 (d, J = 8.9 Hz, H5), 4.28 (d, J = 
4.2 Hz, H3), 4.21 – 4.12 (m, H2), 3.74 (s, OCH3), 2.71 (m, H8), 2.56 (dt, J = 13.4, 6.5 Hz, 
H8’), 2.15 (dd, J = 6.7, 4.4 Hz, H4), 1.44 (t, J = 9.4, 7.4 Hz, SH), 1.24 (t, J = 7.1 Hz, H1), 
1.05 (d, J = 6.8 Hz, H7). 
13
C NMR (126 MHz, CDCl3): δ 14.40, 14.70, 28.47, 39.97, 
55.83, 60.82, 61.31, 114.99, 116.54, 141.22, 153.46, 173.79. 
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Ethyl (2S,3S)-4-(tert-butyldimethylsilyloxy)-2-(p-methoxyphenylamino)-3-methyl-
butanoate (16) Modification of published procedure.
44
 To a solution of compound 11a 
(0.27 g, 1.01 mmol) in DMF (5 mL) was added tert-butyldimethylsilyl chloride (0.78 g, 
5.00 mmol) and imidazole (0.68 g, 10 mmol) at room temperature under argon. After 
stirring for 2 days, the reaction mixture was quenched with water (30 mL). The aqueous 
solution was extracted with EtOAc (3 × 15 mL). The combined organic fractions were 
washed with brine, dried over MgSO4 and concentrated by rotary evaporation. Silica gel 
column chromatography with 5:1 hexanes : EtOAc afforded 16 as a colorless oil (0.33 g, 
0.87 mmol, 86%). TLC: Rf = 0.67 in 2:1 hexanes : EtOAc. 
1
H NMR (500 MHz, CDCl3): δ 
6.75 (m, H6), 6.68 (m, H5), 4.22 (d, J = 3.4 Hz, H3), 4.16 (dd, J = 8.8, 7.2 Hz, H2), 3.73 (s, 
OCH3), 3.63 (dd, J = 10.0, 8.8 Hz, H8), 3.53 (m, H8’), 2.28 – 2.18 (m, H4), 1.24 (t, J = 7.1 
Hz, H1), 0.94 (s, H10), 0.90 (d, J = 7.1 Hz, H7), 0.07 (d, J = 4.5 Hz, H9). 
13
C NMR (126 
MHz, CDCl3): δ 0.03, 11.70, 14.39, 18.39, 26.04, 39.06, 55.84, 59.59, 60.96, 65.16, 
114.87, 115.78, 142.42, 152.81, 174.47. 
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4-Methyl N-(tert-butyloxycarbonyl)-L-aspartate (18) Modification of published 
procedure.
38
 To a stirred suspension of L-aspartic acid (4.00 g, 0.03 mol) in distilled 
MeOH (10 mL) was added acetyl chloride (3.34 g, 0.04 mol) in distilled MeOH (10 mL) 
at 0 
o
C. The reaction mixture was stirred for 1 day from 0 
o
C to room temperature under 
argon. Then the solution was poured into Et2O (60 mL) and cooled for 1 h. The 
precipitate was collected and was dissolved in the mixture of dioxane (60 mL) and water 
(30 mL). Sodium carbonate (6.36 g, 0.06 mmol) was added in one portion at 0 
o
C 
followed by the addition of (Boc)2O (10.90 g, 0.05 mmol). The reaction mixture was 
stirred overnight from 0 
o
C to room temperature. The dioxane was removed and the 
residue was poured into ice-water (60 mL), washed with Et2O (30 mL) to remove 
nonacidic impurities. The aqueous solution was adjusted to pH = 2.5 with saturated 
NaHSO4 (aq) and extracted with Et2O (3 × 45 mL). The combined organic fractions was 
washed with water, dried over MgSO4, filtered and concentrated to afford 18 as a 
colorless oil (5.78 g, 23.40 mmol, 78%) with sufficient purity to be used for the formation 
of compound 19. 
1
H NMR (500 MHz, CDCl3): δ 10.44 (s, COOH), 5.57 (d, J = 8.6 Hz, 
NH), 4.71 – 4.52 (m, H2), 3.70 (s, OCH3), 3.02 (dd, J = 17.1, 4.6 Hz, H1), 2.84 (dd, J = 
17.1, 4.8 Hz, H1’), 1.44 (s, H3). 
13
C NMR (126 MHz, CDCl3): δ 175.71, 171.70, 155.76, 
67.14, 52.25, 49.90, 36.53, 28.40. 
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α-tert-Butyl β-methyl N-(tert-butyloxycarbonyl)-L-aspartate (19) Modification of 
published procedure.
39
 Compound 18 (1.12 g, 4.51 mmol) was dissolved in 
dichloromethane (50 mL) following by the addition of tert-butyl-2,2,2-
trichloroacetimidate (3.95 g, 18.04 mmol) under argon. After overnight stirring at room 
temperature, the solvent was removed by rotary evaporation. Silica gel column 
chromatography with 4:1 hexanes : EtOAc afforded 19 as a colorless oil (1.15 g, 3.79 
mmol, 84%, the oil phase converted to white solid when temperature was down to ~ 8 
°C). TLC: Rf = 0.43 in 3:1 hexanes : EtOAc. 
1
H NMR (500 MHz, CDCl3): δ 5.42 (d, J = 
8.6 Hz, NH), 4.47 – 4.36 (m, H2), 3.66 (s, OCH3), 2.91 (dd, J = 16.6, 4.7 Hz, H1), 2.74 
(dd, J = 16.6, 5.0 Hz, H1’), 1.42 (d, J = 5.7 Hz, H3, 4). 
13
C NMR (126 MHz, CDCl3): δ 
171.43, 170.05, 155.51, 82.40, 79.95, 51.91, 50.68, 37.08, 28.42, 27.98. 
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